Hallucinogens and their therapeutic use: A literature review

Matthew J. Begola, Jason E. Schillerstrom

Research output: Contribution to journalReview article

Abstract

The exploration of possible therapeutic benefits of hallucinogenic substances has undergone a revitalization in the past decade. This literature review investigated the published literature regarding the psychotherapeutic uses of hallucinogens in psychiatric disorders. The results showed that a variety of substances have been evaluated in the treatment of psychiatric disorders, including ayahuasca, ibogaine, ketamine, lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, and psilocybin. The conditions treated ranged from depression to autism, with the largest volume of research dedicated to substance use disorders. The majority of studies that were reviewed demonstrated significant associations with improvement in the conditions investigated. However, it was difficult to draw definitive conclusions as most studies suffered from small sample sizes, inconsistent measures, and poor study design. To properly assess the risks and potential benefits of hallucinogens in psychiatric treatment, there is a need for well designed, standardized studies that demonstrate the impact of hallucinogenic substances on psychiatric conditions.

Original languageEnglish (US)
Pages (from-to)334-346
Number of pages13
JournalJournal of psychiatric practice
Volume25
Issue number5
DOIs
StatePublished - Sep 2019

Keywords

  • 3,4-methylenedioxymethamphetamine (MDMA)
  • Ayahuasca
  • Hallucinogenic drugs
  • Hallucinogens
  • Ibogaine
  • Ketamine
  • Lysergic acid diethylamide (LSD)
  • Psilocybin
  • Psychedelics
  • Psychiatry

ASJC Scopus subject areas

  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'Hallucinogens and their therapeutic use: A literature review'. Together they form a unique fingerprint.

  • Cite this